Search research articles
Contact Us
Filters
Showing results (81-90 of 179) with videos related to
Page
of 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2009
Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas
Stéphanie Puget, Jacques Grill, Alexander Valent, et al.
British Journal of Haematology
|
June 26, 2023
Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib
Nina Prokoph, Jamie D Matthews, Ricky M Trigg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 13, 2023
Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial
Birgit Geoerger, Lynley V Marshall, Karsten Nysom, et al.
Nature Medicine
|
May 29, 2023
Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation
Birgit Geoerger, Manuel Schiff, Virginie Penard-Lacronique, et al.
The Lancet. Oncology
|
November 15, 2021
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study
Matthias Fischer, Lucas Moreno, David S Ziegler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 23, 2021
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium
Claudia Pasqualini, Jonathan Rubino, Caroline Brard, et al.
Journal of Pediatric Hematology/Oncology
|
August 30, 2014
Patients in pediatric phase I and early phase II clinical oncology trials at Gustave Roussy: a 13-year center experience
Francisco Bautista, Angela Di Giannatale, Nathalie Dias-Gastellier, et al.
Neuro-Oncology Advances
|
August 19, 2021
Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma
Victor Pereira, Jacob Torrejon, Dulanjalee Kariyawasam, et al.
Nature Communications
|
July 3, 2026
Spatial transcriptomic atlas of aggressive osteosarcomas reveals shared immune landscape and targetable surface markers
Gaël Moquin-Beaudry, Maria Eugénia Marques Da Costa, Pierre Khneisser, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 20, 2020
Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials - A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting
Jesper Brok, Annelies M C Mavinkurve-Groothuis, Jarno Drost, et al.
Page
of 18
Search research articles
Search
Showing results (81-90 of 179) with videos related to
Sort By:
Page
of 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2009
Candidate genes on chromosome 9q33-34 involved in the progression of childhood ependymomas
Stéphanie Puget, Jacques Grill, Alexander Valent, et al.
British Journal of Haematology
|
June 26, 2023
Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib
Nina Prokoph, Jamie D Matthews, Ricky M Trigg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 13, 2023
Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial
Birgit Geoerger, Lynley V Marshall, Karsten Nysom, et al.
Nature Medicine
|
May 29, 2023
Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation
Birgit Geoerger, Manuel Schiff, Virginie Penard-Lacronique, et al.
The Lancet. Oncology
|
November 15, 2021
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study
Matthias Fischer, Lucas Moreno, David S Ziegler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 23, 2021
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium
Claudia Pasqualini, Jonathan Rubino, Caroline Brard, et al.
Journal of Pediatric Hematology/Oncology
|
August 30, 2014
Patients in pediatric phase I and early phase II clinical oncology trials at Gustave Roussy: a 13-year center experience
Francisco Bautista, Angela Di Giannatale, Nathalie Dias-Gastellier, et al.
Neuro-Oncology Advances
|
August 19, 2021
Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma
Victor Pereira, Jacob Torrejon, Dulanjalee Kariyawasam, et al.
Nature Communications
|
July 3, 2026
Spatial transcriptomic atlas of aggressive osteosarcomas reveals shared immune landscape and targetable surface markers
Gaël Moquin-Beaudry, Maria Eugénia Marques Da Costa, Pierre Khneisser, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 20, 2020
Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials - A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting
Jesper Brok, Annelies M C Mavinkurve-Groothuis, Jarno Drost, et al.
Page
of 18